CNS Pharmaceuticals (NASDAQ:CNSP) Releases Quarterly Earnings Results

CNS Pharmaceuticals (NASDAQ:CNSP) issued its quarterly earnings results on Friday. The company reported ($5.76) EPS for the quarter, Zacks reports.

CNS Pharmaceuticals Trading Up 7.0%

CNSP traded up $0.45 during midday trading on Friday, hitting $6.90. 10,112 shares of the company traded hands, compared to its average volume of 18,341. The company has a market capitalization of $3.93 million, a price-to-earnings ratio of -0.04 and a beta of 2.70. The business has a 50 day simple moving average of $8.23 and a two-hundred day simple moving average of $9.44. CNS Pharmaceuticals has a 52-week low of $4.93 and a 52-week high of $114.00.

Institutional Trading of CNS Pharmaceuticals

An institutional investor recently bought a new position in CNS Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 406,000 shares of the company’s stock, valued at approximately $335,000. Armistice Capital LLC owned approximately 90.22% of CNS Pharmaceuticals at the end of the most recent reporting period. 14.02% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen lowered shares of CNS Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 5th. Maxim Group upgraded shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Friday, September 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CNS Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.